Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189197 | 1.00 | CXCR2 (0.71) | CXCR2CCR7 | |
| SCHEMBL5189173 | 0.91 | CXCR2 (0.72) | CXCR2CCR7 | |
| SCHEMBL5189438 | 0.90 | CXCR2 (0.71) | CXCR2CCR7 | |
| SCHEMBL5191298 | 0.89 | CXCR2 (0.69) | CXCR2CCR7 | |
| SCHEMBL5189404 | 0.88 | CXCR2 (0.73) | CXCR2CCR7 | |
| SCHEMBL5189423 | 0.87 | CXCR2 (0.68) | CXCR2CCR7 | |
| SCHEMBL3850177 | 0.87 | CXCR2 (0.77) | CXCR2CCR7 | |
| SCHEMBL3856461 | 0.86 | CXCR2 (0.73) | CXCR2CCR7 | |
| SCHEMBL5190675 | 0.86 | CXCR2 (0.76) | CXCR2CCR7 | |
| SCHEMBL5190682 | 0.86 | CXCR2 (0.76) | CXCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419158-B1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | claimed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | claimed |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | BONNERT ROGER VICTOR (GB) | 2005-01-13 | — | — | US | claimed |
| EP-1419158-B1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | BONNERT ROGER VICTOR (GB) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | CCR5, CXCR3, CCR2 | CXCR2 11/4885CCR7 6/4885 |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | CXCR2 11/4885CCR7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.